You are here:Home-Research Areas-Infection-Bacterial Infection

Request The Product List ofBacterial Infection Bacterial Infection

Cat. No. Product Name CAS No. Information
PC-63299

Bedaquiline fumarate

845533-86-0

Bedaquiline fumarate (R403323, TMC207 fumarate, R207910 fumarate) is a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections.

Bacterial Infection

Approved

PC-62613

Nacubactam

2007923-17-1

Nacubactam (OP 0595, RG 6080, RO 7079901) is a diazabicyclooctane that inhibits class A and C β-lactamases with IC50 of <1 uM, also acts as a PBP2-active antibacterial; exhibits MICs of 0.5 to 4 μg/ml for most members of the family Enterobacteriaceae, owing to inhibition of PBP2; has MICs of 1-4 mg/ml for Escherichia coli, Enterobacter, Citrobacter and Klebsiella spp; increases the antibacterial activity of cefepime in both in vitro and in vivo.

Bacterial Infection

Phase 1 Clinical

PC-61388

Macozinone

1377239-83-2

Macozinone (PBTZ-169, PBTZ169) is a potent, second-generation antituberculosis agent that inhibits DprE1 and displays nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro; PBTZ169 is less cytotoxic than BTZ043 and shows significantly better efficacy at lower concentrations in the murine model of chronic TB, inhibits DprE1 more efficiently than BTZ043.

Bacterial Infection

Phase 2 Clinical

PC-61371

Contezolid

1112968-42-9

Contezolid (MRX I) is an orally active oxazolidinone agent with antibacterial activity Gram-positive pathogens, including MRSA, penicillin-PRSP, PISP, and vancomycin-resistant enterococci (VRE) with MIC of 0.25-4 ug/mL; demonstrates the same or better efficacy than linezolid in both systemic and local infection models against the tested strains.

Bacterial Infection

Phase 3 Clinical

PC-61295

Murepavadin

944252-63-5

Murepavadin (POL7080) is a highly potent, specific, macrocycle Pseudomonas antibiotic for the treatment of bacterial infections caused by Pseudomonas aeruginosa.

Bacterial Infection

Phase 3 Clinical

PC-61003

ETX2514

1467157-21-6

ETX2514 (ETX 2514, ETX-2514) is a covalent, broad-spectrum β-lactamase inhibitor with IC50 of 4, 14 and 190 nM for class A KPC-2, class C AmpC and class D OXA-24, respectively; potently inhibit clinically relevant class A, C and D β-lactamases and penicillin-binding proteins, resulting in intrinsic antibacterial activity against Enterobacteriaceae and restoration of β-lactam activity in a broad range of MDR Gram-negative pathogens; demonstrates potent antibacterial activity, in vivo efficacy against MDR A. baumannii infections combined with sulbactam.

Bacterial Infection

Phase 1 Clinical

PC-60091

GSK-656

2131798-13-3

GSK-656 (GSK-3036656, GSK656) is a potent, highly selective,orally bioavailable Mtb Leucyl-tRNA synthetase (LeuRS) with IC50 of 0.2 uM; displays no significant activity for human mitochondrial LeuRS and human cytoplasmic LeuRS (IC50>100 uM); shows potent antitubercular activity (Mtb H37Rv IC50=0.08 uM) in vitro; exhibits remarkable PK profiles and efficacy against Mtb in mouse TB infection models.

Bacterial Infection

Phase 1 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com